OncoMatch/Clinical Trials/NCT05703178
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
Is NCT05703178 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for breast cancer.
The main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are taking an AI medication, and who have arthralgia. Arthralgia is a type of joint, bone, and muscle pain that is a common side effect of AI medications. The main questions it aims to answer are: 1. Whether online pain coping skills training reduces the severity of pain and the interference it causes in women's daily lives. 2. Whether online pain coping skills training improves emotional distress, quality of life, and adherence to AI medications. 3. Whether benefits of online pain coping skills training are at least partially caused by women's increased confidence that they can manage their pain and a reduction in unhelpful thinking patterns about pain. 4. Whether online pain coping skills training improves effects of AI medications on sleep problems and symptoms of menopause like hot flashes and night sweats. Participants can complete all parts of the study at home. They will: 1. Complete four sets of questionnaires throughout the study, which will take about 9 to 10 months. 2. Attend 3 meetings in the first month of the study, all of which can be held via a video conference. 3. Use an electronic pill bottle to track their use of their AI medication. 4. Be randomized (like flipping a coin) to one of two study arms: They will either receive education about AIs and arthralgia or they will receive this education along with access to an online pain coping skills training program. Research will compare the education group to the education plus online pain coping skills training group to see if online pain coping skills training has the benefits mentioned above.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage 0, I, II, III
Excluded: Stage IV
Diagnosed with Stage 0-III hormone receptor positive breast cancer; Evidence of metastatic disease [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery — primary
Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy)
Must have received: chemotherapy — primary
Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy)
Must have received: radiation therapy — primary
Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy)
Cannot have received: chemotherapy
Completed chemotherapy or radiation therapy less than four weeks prior to enrollment
Cannot have received: radiation therapy
Completed chemotherapy or radiation therapy less than four weeks prior to enrollment
Cannot have received: surgery
Exception: minor surgeries may be allowed more recently than 8 weeks at the discretion of the study team
Completed surgery less than 8 weeks prior to enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwestern University · Chicago, Illinois
- Duke University · Durham, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify